chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Went to bed on 1/6/2021 and woke up in middle of night with severe chills and nausea.  Got out of bed at 6 am on 1/7/2021 with temp of 102.8 , very sore left arm that was swollen,  severe headache,  and body aches and fatigue.  Symptoms continued all day.  Was able to get temp down to 101 with Tylenol and ibuprofen but it would return to 102 once med wore off.  Headache all day with out relief.  Used Ice pack on left arm to relieve swelling and pain.  Symptoms continued on 1/8/2021 with temp up to 101.8, severe HA, sore and swollen arm, body aches and fatigue.  Low grade temp on 1/9/2021 of 100.5, headache, sore arm with less swelling, less body aches and less fatigue.  No temp on 1/10/2021 but headache and sore arm continued.  Headache resolved by 1/11/2021.  Sore arm lessened every day.  It is still slightly sore only with palpation.
Fever, chills, eyes bloodshot, sore throat, hoarseness, cough - started approximately 5:30 same night. Symptoms progressive thru evening lasted x 6 hours, except fever still thru the night. Took ibuprofen.
Pt describes delayed onset of pain, started about a week after the shot . Describes tenderness/soreness like a bruise deep inside injection site. Patient thinks the injection might have been given IM, however the pharmacist did tell the patient at the time of injection that is was a sub q shot. Pt alleges that is was given in the deltoid , same are on opposite arm as the Shingrix shot she received that day.  Pt say affecting her sleep.
Nauseous before getting the vaccine; This spontaneous case was reported by a patient family member or friend and describes the occurrence of NAUSEA (Nauseous before getting the vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Nauseous.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced NAUSEA (Nauseous before getting the vaccine). At the time of the report, NAUSEA (Nauseous before getting the vaccine) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant and treatment information were not provided.
VARlVAX that underwent a temperature excursion was administered; No additional adverse effect reported; This spontaneous report as received from a licenced practical nurse refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.  On 31-MAR-2021, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) lot # T027302, expiration date: 12-AUG-2022 (dose, route of administration and anatomical location were not reported) for prophylaxis.  Administered dose of vaccine underwent the temperature excursion: from -15 to -10 degrees Celsius for 2 hours and 30 minutes. Digital data logger was involved. There were no previous excursions.
This spontaneous report was received from a register nurse, refers to an unknown number of patients, of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On an unknown date the patients were vaccinated with improperly stored doses of VARIVAX (Merck), (lot#, expiration date, strength, dosage and route were not reported). Concomitant therapy was not reported. No adverse effects reported. No product quality complaint was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Persistent diarrhea, nausea, fatigue, headache, chills, sweats onset with nausea immediately following vaccination. Diarrhea resolved the night of the vaccine (11/11/2021). Remainder of symptoms currently persisting.
PATIENT RECIEVED INCORRECTLY STORED VACCINE; REQUIRES RE-ADMINISTRATION
Injection site reaction to left shoulder with swelling, redness and warmth to touch after the 8th day of administration of Moderna Covid-19 Vaccine.
Shaking chills, weakness, headache, generalized aches. Started approx. 4 hours post injection. Per mom, as of 02/24/17 all symptoms resolved.
Information has been received from a licensed practical nurse referring to multiple unspecified patients of unknown age and gender. Information regarding concomitant medication, medical history and drug reactions/allergies was not reported. On unknown dates, the patients might have received doses of improperly stored ROTATEQ (lot # L027070 with expiration date 30-APR-2017; lot # L033548 with expiration date 14-MAY-2017; dose unknown; oral). The vaccine was exposed to 31 Fahrenheit for 40 minutes (incorrect product storage). There was no prior excursion. Data logger was unknown. No adverse effects were reported. At the reporting time, the reporter did not sure if the vaccine was administered. This is one of several reports received from the same reporter. Additional information has been requested.
From initial information received on 09/29/2004 and 10/05/2004 from a healthcare professional regarding an adverse event occurring in the USA, it was reported that a 43 year old female patient received a dose of Tetanus Toxoid, lot number U1048CA, administered intra-dermally in error instead of Tuberculin PPD on 08/24/2004.  The site of administration was not reported.  Two days later, on 08/26/2004, the patient developed redness, itching and papular lesions at the site of administration.  She was treated with an unspecified topical cream for the itching and recovered from these events.  Further information is not anticipated, this case is considered closed.
Tightness in throat and fast heart rate.  No difficulty breathing.  No swelling of tongue.  No difficulty swallowing.
3/25/21,Thursday at around 4:00 PM was when I received my 1st dose of the Pfizer/BioNTech COVID vaccine 3/26/21, Friday at around 6:00 PM, I developed a fever of 100.4 for which I took Tylenol. The fever resolved only to come back after 4 or 6 hrs. It was accompanied by chills, general feeling of being unwell and poor appetite.  These symptoms continued until 3/27/21 (Saturday), 3/28/21 (Sunday), 3/29/21 (Monday), 3/30/21 (Tuesday). 3/30/21, Tuesday, I sent a mesage to my PCP, informing her of the above.  I lso went to Urgent Care and reported the same. There I was swabbed (nasopharyngeal) for COVID testing which turned out positive. As of this reporting, symptoms of fever and chills, are still present.
1st dose on 8-Aug-2019, 2nd on 3-Aug-2022; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 68-year-old female patient who received Herpes zoster (Shingrix) (batch number XM22Z, expiry date 31st August 2023) for prophylaxis.   Previously administered products included Shingrix (The patient received 1st dose on 8th August 2019 ).   On 3rd August 2022, the patient received the 2nd dose of Shingrix. On 3rd August 2022, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK Receipt Date: 08-AUG-2022. Reporter's Comments: The patient received Shingrix in left deltoid. The reporter wanted  to inquire if it was ok that the patient received the second dose three years later. The reporter gave consent to follow up. Additional Supportive Information: The patient received 2nd dose of Shingrix late than recommended time frame, which led to which led to lengthening of interval between vaccine doses
Mother of PT described that at approximately 19:00 hr, on 11/09/23, PT began to become irritable, actively avoided rolling or crawling on the right side of his body and felt warm to the touch. Mother evaluated PT's temperature and right leg, noting his temperature measured 103°F, as well as, observed a small red irritation on PT's upper right thigh. She also stated that when she touched the irritated area the PT would begin to cry more aggressively. Throughout that night, mother and father of PT switched between pediatric ibuprofen and Tylenol to help reduce PT fever. The following day, 11/10/2023, PT mother states that his fever had reduced to 100°F and the previously small red irritation had grown. PT's mother described a darker red-colored bump where the small red irritation previously was. Surrounding the bump, approximately 3mm, redness and irritation of the skin was observed in a rectangular shape, measuring, approximately, 4mm laterally and 1mm vertically.  PT continued to demonstrate discomfort at the location of irritation as well as fever persisted throughout the day.   PT's mother contacted the office, at approximately 15:45hr on 11/10/23, concerned because PT's fever had not changed throughout the day and  described that the skin irritation surrounding the darkened bump seemed to continue to spread in PT's upper right thigh. PT's mother spoke with Dr where she described her observations as well as provided a photograph of PT's upper right thigh to ensure the physician could understand her description of the irritated area. Dr evaluated the image and the information that was provided to him. Dr stated to PT's mother that he would send a prescription for amoxicillin to PT's pharmacy to help lower the skin irritation and fever, stating that the PT may be experiencing possible cellulitis, as well as PT is potentially allergic to the MMRV (ProQuad) vaccination. The prescription of Amoxicillin Suspension Reconstituted, 400mg/5mL, Orally, 42mL, 3mL, Twice a day for 7 days, was sent to the pharmacy later that day.   Today, at 9:00 hr, PT?s mother contacted the office stating that there had been an issue with the telephone system of the pharmacy the day prior and asked if we could resubmit the prescription to make certain the prescription is received. She also stated that PT?s symptoms had not changed much since the day prior. PT?s temperature had stayed at around 100°F, the darker colored bump was still observed and the skin irritation had neither grown or shrunk since the last time she contacted the office. Dr resubmitted the prescription and PT?s mother stated she would pick the medication up later in the morning. She ensured that she would continue to keep the physician informed with any major changes in PT?s health.
arm sore; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date 26Mar2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 26Mar2021, outcome "unknown", described as "arm sore".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pt had major typical case of varicella iwth hundreds of lesions all over her body in typica, pre-vaccine fashion.
Reported that had back pain w/in 24 hrs, episodes of breast tenderness rt w/poss nodes enlarged on lateral aspect of rt breast, facial flushing, pain anticubital areas both arms, & in both knees-no swelling in areas; Also c/o numbness toes;
Swollen glans in neck and sore throat , on going pain at injection site in right arm
Stomach upset, dizzy/whoozy, weakness, faint, saw stars, had to sit down for 45 minutes.
Guillain-Barre syndrome; Initial information was received on 17-Oct-2021 regarding an unsolicited valid serious case received from a consumer/non-healthcare professional via the social media.   This case involves a patient (unknown demographics) who reported that 22 years ago he/she experienced Guillain-Barre Syndrome after receiving INFLUENZA VACCINE.  It was unknown if the patient had any medical history, concomitant disease or risk factor.  The patient's medical treatment, vaccination, concomitant medication and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date: not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a serious Guillain-Barre Syndrome (unknown latency) following the administration of INFLUENZA VACCINE. This event was assessed as medically significant.  It was reported that patient got Guillain-Barre Syndrome from a flu shot 22 years ago from the time of reporting.  It was unknown if the patient experienced any additional symptoms/events.  It was unknown if there were lab data/results available.  It was not reported if the patient received a corrective treatment.  At time of reporting, the outcome was unknown for the reported event.  Information on the batch number was requested.; Sender's Comments: This case involves a patient (unknown demographics) who had Guillain-Barre Syndrome, after receiving INFLUENZA VACCINE (unknown manufacturer). The time to onset is unknown. Additional information regarding patient's medical history, condition at the time of the events, lab data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of the suspect vaccine cannot be assessed.
pt developed a large 6 in x 4 in rash from the injection site within 24hrs of receiving infection. Mom treated at home w/ cold compress w/ little relief. Pt seen in office today and advised to give oral benadryl + continue cool compresses w/ referral to allergist made
Patient reported today (9/17/2020) that on 8/25/2020 she noticed a knot, swelling, and tenderness at the site of her HPV injection that occurred 4 weeks prior to incident (8/4/2020). Patient had her PET scan due to her diagnosis of Hodgkin's Lymphoma and the site of the injection showed up on the PET scan.
Headache, Myalgia, Arthralgia, Fever, chills. all symptoms x 3 days Narrative:
Breakthrough case admission after 3 vaccines Pfizer 4/1/21 lot# Ew0153;  Pfizer 5/2/21 lot@ Ew0176;  Pfizer 12/17/21 lot# FJ8757
pt had right leg swelling and pain starting  on 03-22-21 and presented for medical care on 03-29-21 was found to have elevated d-Dimers and Doppler RLE showed occlusive clot in right peroneal vein and non-occlusive clot in right popliteal vein
Headache, Myalgia, Arthralgia,  fatigue Narrative:  Other Relevant History:
increased allergies; This is a spontaneous report from Pfizer sponsored program via a contactable consumer (patient, self-reported).  A male patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number and expiry date were not reported), via an unspecified route of administration, on an unspecified date, as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient stated that he was scheduled for his 2nd Pfizer vaccine this weekend. His allergies were kicking in (increased allergies) and would like to know if it was ok to take claritin. Outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
had them, had the shingles shot/ suspected vaccination failure; had them; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The patient self reported the case. The age at vaccination was not reported. The patient received shingle shot and got shingles this year. The follow up would not be possible as no contact details were available. This case was considered to be a suspected vaccination failure case, as the details regarding completion of primary vaccination schedule and time to onset and laboratory confirmation for shingles were unknown.
got mine last week and it hurt like the dickens for 2w days; Initial information received on 18-Oct-2021 regarding an unsolicited valid non-serious case received from a consumer or non-healthcare professional via social media.  This case involved a patient (unknown demographic) who reported that "got mine last week and it hurt like the dickens for 2w days" (pain) after receiving INFLUENZA VACCINE.  It was unknown if the patient had any medical history, concomitant disease or risk factor.   The patient past medical treatment, vaccination, concomitant medication and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) [lot number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date the patient developed a non-serious "got mine last week and it hurt like the dickens for 2w days" (pain) (unknown latency) duration 2 week days following the administration of INFLUENZA VACCINE.  It was unknown if there were lab data/results available.  It was unknown if the patient experienced any additional symptoms/events.   It was not reported if the patient received a corrective treatment for the event of pain.  At time of reporting, the outcome was unknown for the event pain.  There will be no information available on the batch number for this case.
This is a literature case, initially received on 19-Feb-2019, concerning a 2-year-old, male child. The study describes the reports of anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS) during 1990-2016. A descriptive analysis, including history of hypersensitivity (anaphylaxis, respiratory allergies, and drug allergies) and vaccines given were performed. The patient's medical history included premature birth at 33 weeks of gestation, hypoplastic left heart syndrome with subsequent cavopulmonary shunt procedure. The current conditions of the patient included periodic cyanosis. On an unspecified date, the patient was administered INN Flu Vaccine Seasonal (anatomical location, dose, route of administration, batch number, manufacturer, trade name and expiry date: not reported) for an unknown indication. On the same day, the patient was also administered a combined non-company suspect vaccine, Measles vaccine;Mumps vaccine;Rubella vaccine;Varicella zoster vaccine (anatomical location, dose, route of administration, batch number, manufacturer, trade name and expiry date: not reported) for an unknown indication. On the same day, 20 minutes after the vaccination, the patient experienced a cardiopulmonary arrest and the patient died. Autopsy was performed, and the cause of death was reported as anaphylactic reaction (related). On post-mortem laboratory tests revealed an increased serum tryptase level. The outcome of the event cardiopulmonary arrest was not reported. The reporter assessed this case as serious (death).; Reporter's Comments: A 2-year-old, male patient with medical history/concurrent condition (premature birth at 33 weeks of gestation, hypoplastic left heart syndrome with subsequent cavopulmonary shunt procedure and periodic cyanosis) experienced fatal cardiopulmonary arrest, 20 minutes after administration of INN Flu Vaccine. The autopsy reported the cause of death as anaphylactic reaction. The case meets level 2 of Brighton Collaboration criteria of diagnostic certainty for anaphylactic reaction. Considering the plausible temporal relationship between vaccination and reported fatal events (anaphylactic reaction and cardiopulmonary arrest) and lack of alternative more plausible causes, the company conservatively assessed the events as possibly related to suspect vaccine. However, co-administered combined measles, mumps, rubella and varicella vaccine was considered as non company suspect in this case. The company assessed the event 'anaphylactic reaction' as serious (medically significant).; Reported Cause(s) of Death: Anaphylactic reaction.
pt recvd vax & 24 hrs p/vax exp fever & rash; pt seen by MD;
Information has been received from a 21 year old female who on 12-OCT-2007 was vaccinated with a first dose of Gardasil (Lot # not reported).  Concomitant therapy included venlafaxine HC1 (EFFEXOR).  The patient reported that on 13-OCT-2007, the day after her vaccination with Gardasil, her fingers and lips were swollen and itchy.  The patient reported that she recovered on 14-OCT-2007.  The patient sought unspecified medical attention.  Additional information has been requested.
Received COVID vaccine #1 (Pfizer for 5-11 yr) on 11/22/21 and two days later on 11/24/21, parents state when asked to perform simple task, he became significantly emotional, laid on garage cement floor, curled up and continued to cry for 2-3 hours. He has not had episodes like this previously. The emotional episodes has continue to reoccur since 11/24/21. He has previously had intermittent headaches for about a year and headaches have gradually worsened since 11/2021. He has had fatigue for the past several months that has worsened since 11/2021.
Mild headache. Took 600mg ibuprofen after an hour, and pain quickly subsided. Has not returned. No other effects.
Severe deep aching pain in muscle of upper left arm developed within the first couple of days after the injection and has continued to the present (currently about 7 weeks duration). Some muscle wasting in upper left arm also noted by doctor.
Reported dizziness, elevated fever (100-102) x 8 days, starting approx 4JAN91. Also reports swollen glands, stiff neck, basal headache-relieved by Tylenol.
Site: Redness at Injection Site-Mild, Systemic: Fainting / Unresponsive-Medium, Systemic: Flushed / Sweating-Severe, Additional Details: Patient fainted while sitting down aproxmiately 10 mintues after getting shot. Patient was out for maybe 1 minute. we called 911 and when patient came too he camcelled the 911 call. He informed us he has fainted before due to his anxiety of vaccinations. Patient sat for 40 more minures then left. I followed up with a phone call today to see how patient was doing. there was no answer. I left a message
Headache over the crown of the headache 1 day following the 1st injection, continued headache now, 2 weeks later
Patient with2 COVID vaccines who had a positive COVID PCR on admission to hospital.  Provider d/c note:  "59 YO female with h/o intellectual disability, nonambulatory status, seizure disorder on Dilantin, anxiety admitted 10/31 for multiple seizures at assistive living facility after her years since previous seizure.  CT head showing no acute intracranial abnormality although with continued chronic findings of ventricular prominence as well as extra-axial fluid overlying left cerebellum.  Neurology consulted and increase patient's dose of Dilantin from 200 mg to 300 mg.  There were initial concerns for urinary tract infection but urine culture came back negative and antibiotics were discontinued.  Patient positive for COVID on testing on admission although had been symptomatic apparently on 10/27.  Patient never hypoxic throughout hospitalization and only symptoms noted during hospitalization were fatigue which was improved by time of discharge.  At time of discharge patient was alert and talking in simple one-word answers for short sentences and answering simple questions such as her name and appearing to be at her baseline self.  Patient discharged back to assistive living facility with follow-up with Neurology on 11/17."